Solid Biosciences Expects Patient Dosing In Q1 In IMPACT DUCHENNE Trial, Additional Data Anticipated For hase 1/2 INSPIRE DUCHENNE Study In Mid-2026
Benzinga Newsdesk 9 months ago
News
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will provide a corporate update outlining progress
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will provide a corporate update outlining progress in advancing its neuromuscular and cardiac gene therapy programs in a presentation delivered by Bo Cumbo, President and CEO, at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET).